Skip to main content
Scott Dahlbeck, MD, Radiation Oncology, San Antonio, TX

ScottW.DahlbeckMD

Radiation Oncology • San Antonio, TX

Urologic Cancer

UMC Southwest Cancer Center

Join to view full profile

Dr. Dahlbeck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Dahlbeck's full profile

Already have an account?

Education & Training

  • Kaiser Permanente Southern California (Los Angeles)
    Kaiser Permanente Southern California (Los Angeles)Residency, Radiation Oncology, 1999 - 2003
  • Hennepin Healthcare
    Hennepin HealthcareResidency, Family Medicine, 1993 - 1995
  • University of Minnesota
    University of MinnesotaResidency, Radiation Oncology, 1993 - 1993
  • Methodist Hospital (Houston)
    Methodist Hospital (Houston)Internship, Family Medicine, 1992 - 1993
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 1992

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1986 - 2026
  • CA State Medical License
    CA State Medical License 1999 - 2024
  • NM State Medical License
    NM State Medical License 2003 - 2006
  • MN State Medical License
    MN State Medical License 1994 - 1999
  • American Board of Radiology Radiation Oncology

Publications & Presentations

PubMed

Press Mentions

  • Kiromic Announces Expansion of in-House Cell Therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
    Kiromic Announces Expansion of in-House Cell Therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing OfficerJune 7th, 2021
  • Kiromic Announces FDA IND Submission First-in-Human, AI Derived Off-the-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
    Kiromic Announces FDA IND Submission First-in-Human, AI Derived Off-the-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second QuarterMay 24th, 2021
  • Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T Cell Therapies for Multiple Solid Tumors
    Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T Cell Therapies for Multiple Solid TumorsMarch 9th, 2021
  • Join now to see all

Dr. Scott Dahlbeck, Dr. Scott Dahlbeck, MD, Dr. S Dahlbeck, Dr. Scott W. Dahlbeck